Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
about
Activator protein 1 promotes gemcitabine‑induced apoptosis in pancreatic cancer by upregulating its downstream target BimA Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.Centromere protein U is a potential target for gene therapy of human bladder cancer.Extension of the Calvert formula to patients with severe renal insufficiency.
P2860
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase I dose-escalation study ...... patients with ovarian cancer.
@ast
Phase I dose-escalation study ...... patients with ovarian cancer.
@en
type
label
Phase I dose-escalation study ...... patients with ovarian cancer.
@ast
Phase I dose-escalation study ...... patients with ovarian cancer.
@en
prefLabel
Phase I dose-escalation study ...... patients with ovarian cancer.
@ast
Phase I dose-escalation study ...... patients with ovarian cancer.
@en
P2093
P1433
P1476
Phase I dose-escalation study ...... n patients with ovarian cancer
@en
P2093
Alwin D R Huitema
Jan H M Schellens
Jos H Beijnen
Stephan A Veltkamp
Suzanne Leijen
P304
P356
10.1016/J.YGYNO.2013.05.001
P407
P577
2013-05-09T00:00:00Z